ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,930.85
0.00%
US Tech 100
20,818.00
0.35%
다우존스 지수
42,840.26
0.00%
Bitcoin
94,947.19
-0.17%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. MoonLake Immunotherapeutics (MLTX)

  7. MoonLake Immunotherapeutics (MLTX) 뉴스

MLTX

MoonLake Immunotherapeut... (MLTX)

MoonLake Immunotherapeutics
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:MLTX
일자시간출처헤드라인심볼기업
2024/12/1906:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/1322:00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisNASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/0721:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/0721:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/0721:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
2024/10/0905:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/09/1120:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/09/0920:00GlobeNewswire Inc.MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11NASDAQ:MLTXMoonLake Immunotherapeutics
2024/08/0721:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/08/0721:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/08/0721:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11NASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/1105:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/1021:00GlobeNewswire Inc.MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic ArthritisNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0806:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0806:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0805:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0805:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0620:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/1621:00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0721:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0721:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0721:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0720:57Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/04/1020:00Business WireMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsNASDAQ:MLTXMoonLake Immunotherapeutics
2024/04/1020:00GlobeNewswire Inc.MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions NASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/1121:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/1101:00GlobeNewswire Inc.MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayNASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/0422:00GlobeNewswire Inc.MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024NASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/0109:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/0109:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
 검색 관련기사 보기:NASDAQ:MLTX

최근 히스토리

USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AAPL
Apple
AMEX
XLF
Financial Select Sector
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
FX
USDJPY
US Dollar vs Yen
NYSE
MCD
McDonalds
NYSE
XOM
Exxon Mobil
NYSE
VZ
Verizon Communications
COIN
ADAUSD
Cardano
USOTC
ADDYY
Adidas (QX)
NASDAQ
GOOGL
Alphabet
FX
USDGBP
US Dollar vs Sterling
COIN
BTCUSD
Bitcoin
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유